ROCO
4197
Market cap8mUSD
Jul 09, Last price
8.73TWD
1D
-3.00%
1Q
6.46%
Jan 2017
-33.05%
IPO
-71.38%
Name
Visgeneer Inc
Chart & Performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Visgeneer Inc. specializes in comprehensive health and wellness solutions, with expertise spanning medical devices, cosmetics and skincare, bacterial fermentation, and cancer gene diagnostics. Its market presence covers both Europe and Asia. Within the medical device sector, the firm supplies diagnostic systems capable of monitoring vital health indicators such as blood glucose, ketones, uric acid, and cholesterol. The company boasts an extensive cosmetic and skincare portfolio, featuring diverse facial masks like wood pulp, invisible, black, pure cloth, and bio-cellulose varieties. This portfolio extends to a wide array of creams (e.g., facial, night, day, anti-wrinkle, repairing, whitening, exfoliating), alongside toners, lotions, and specialized essences. Body care offerings include lotions and therapeutic spa clay masks, complemented by sun protection solutions in physical, chemical, and broad-spectrum formulations. Cleansing agents comprise face washes, creams, mousses, gels, shampoos, and body cleansers. Further specialized products encompass hand and knee creams, foot and hand masks, glucosamine creams, anti-acne solutions, feminine hygiene lotions, general skincare products, and nutritional capsules for skin and hair. Customized skincare formulations are also part of its service. Visgeneer also promotes its distinct brands, including the eBmonitor Blood Monitoring System, CoreSence Skincare, BOWIL Skincare, and ZeaSight EU Patent Zeaxanthin. Beyond its comprehensive product lines, the company extends its expertise through contract manufacturing services. Established in 2005, Visgeneer Inc. maintains its headquarters in Hsinchu City, Taiwan.
Valuation
Title TWD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | |||||||
Revenues | |||||||
Cost of revenue | |||||||
Unusual Expense (Income) | |||||||
NOPBT | |||||||
NOPBT Margin | |||||||
Operating Taxes | |||||||
Tax Rate | |||||||
NOPAT | |||||||
Net income | |||||||
Dividends | |||||||
Dividend yield | |||||||
Proceeds from repurchase of equity | |||||||
BB yield | |||||||
| Debt | |||||||
Debt current | |||||||
Long-term debt | |||||||
Deferred revenue | |||||||
Other long-term liabilities | |||||||
Net debt | |||||||
| Cash flow | |||||||
Cash from operating activities | |||||||
CAPEX | |||||||
Cash from investing activities | |||||||
Cash from financing activities | |||||||
FCF | |||||||
| Balance | |||||||
Cash | |||||||
Long term investments | |||||||
Excess cash | |||||||
Stockholders' equity | |||||||
Invested Capital | |||||||
ROIC | |||||||
ROCE | |||||||
| EV | |||||||
Common stock shares outstanding | |||||||
Price | |||||||
Market cap | |||||||
EV | |||||||
EBITDA | |||||||
EV/EBITDA | |||||||
Interest | |||||||
Interest/NOPBT | |||||||